Pegylated liposomal doxorubicin (Doxil®) versus doxorubicin for first-line treatment of metastatic breast cancer

Clinical Breast Cancer

Volumn 3, Issue 3, 2002, Pages 183-184

  Maung, Kavita ^a   O'Shaughnessy, Joyce ^a   Overmoyer, Beth ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DOXORUBICIN; LIPOSOME;

ARTICLE; BLOOD TOXICITY; BREAST METASTASIS; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY;

EID: 0036695233     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1526-8209(11)70179-3     Document Type: Article

References (4)

1. Allen TM, Hansen C, Martin F, et al. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1991; 1066:29-36.
2. Vaage J, Barbera-Guillem E, Abra R, et al. Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 1994; 73:1478-1484.
3. Ranson MR, Carmichael J, O'Byrne K, et al. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 1997; 15:3185-3191.
4. Wigler N, Inbar M, O'Brien M, et al. Reduced cardiac toxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin (Caelyx/Doxil) versus doxorubicin for first-line treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 2002; 21:45a (Abstract #177).